Scaling Spatial Biology Research
The Era Beyond “High-Plex” Alone
In recent years, research utilizing spatial proteomics and multiplex imaging has rapidly expanded beyond exploratory studies into larger-scale clinical studies and cohort-based research.
In particular, the scale and scope of these studies have evolved significantly, including comparative analyses across large cohorts, biomarker validation in clinical trials, multi-site collaborative studies, patient subgroup classification in drug discovery, and operation within multi-user environments.
At the same time, new operational challenges have emerged in research settings.
The Era Where “Visualization” Alone Is Not Enough
Advances in spatial analysis technologies have made it possible to visualize tissue microenvironments in unprecedented detail. However, as studies continue to scale up, simply being capable of “high-plex analysis” is no longer sufficient in many cases.
Today, many laboratories face operational challenges such as increasing sample volumes, longer turnaround times, operator workload, variability in data quality, sample traceability management, operational efficiency in shared facilities, and high running costs. Particularly in clinical research, attention is shifting beyond the analytical performance of individual samples toward whether large numbers of samples can be processed continuously with stable quality.
Growing Demand for “Clinical Research Readiness” in Spatial Analysis
Traditionally, spatial analysis technologies were primarily used for relatively small-scale research applications. However, current needs are evolving from studies involving dozens of samples to those involving hundreds, from exploratory research toward clinical applications, and from single-laboratory use toward core facility deployment.
As a result, factors such as high-throughput capability, long-duration automated operation, reproducibility, workflow standardization, labor reduction, and multi-site compatibility are becoming increasingly important considerations in system selection and workflow design.
Why “Large-Scale Operation” Is Now Drawing Attention
In spatial biology research, it is no longer enough to simply observe many biomarkers simultaneously. Increasingly, the key question is whether the resulting data can be managed effectively at the scale required for clinical research.
For example, delays in analysis can impact entire large-cohort studies, while clinical trials require highly consistent data quality. In addition, multi-site collaborative studies demand workflow standardization, and shared core facilities must support multiple users simultaneously.
Against this backdrop, spatial analysis systems are increasingly expected to serve not only as research tools, but also as part of the infrastructure supporting clinical research.
RareCyte Webinar to Explore Spatial Analysis for Large-Scale Clinical Research
In response to these growing demands, RareCyte will host a webinar focused on spatial analysis approaches for large-scale clinical research applications.
The webinar will feature Dr. Tad George, Senior Vice President of Biology R&D at RareCyte, who is scheduled to discuss challenges associated with large-scale studies, scaling spatial analysis workflows, approaches to high-throughput operation, support for multi-user environments, and operational strategies designed with clinical research applications in mind.
The session will also introduce the design philosophy behind RareCyte’s high-throughput platform, Orion HT, including the considerations emphasized for clinical research applications.
Webinar Information
Title:
Clinical-Scale Spatial Biology with Orion HT
Date & Time:
Tuesday, June 2, 2026
12 pm EDT / 9 am PDT
Format:
Zoom Webinar (Online)
Registration:
Register here
Recommended For
・Researchers conducting large cohort studies
・Scientists seeking higher-throughput spatial analysis workflows
・Users facing operational challenges in multiplex IF workflows
・Organizations planning biomarker programs for clinical trials
・Core facility managers and operators
・Facilities supporting multi-user spatial biology environments
・Researchers interested in the clinical application of spatial proteomics
Speaker
Tad George, PhD
Senior Vice President, Biology R&D, RareCyte, Inc.
Dr. Tad George has more than 15 years of experience developing and expanding scientific markets for novel analytical platform technologies spanning basic research, drug discovery, and clinical applications.
He has extensive experience translating innovative analytical technologies from research use into real-world applications in drug discovery and clinical research, contributing to the advancement of spatial biology and cellular analysis technologies.
Prior to joining RareCyte, Dr. George held leadership positions at Biodesy, Inc. and DVS Sciences. He also served as Director of Biology at Amnis Corporation, where he contributed to technology development in cell imaging and flow cytometry.
Academically, Dr. George earned his B.A. in Biochemistry from the University of Texas at Austin and his Ph.D. in Immunology from UT Southwestern Medical Center at Dallas. He subsequently completed postdoctoral training at Immunex Corp. in Seattle.
At RareCyte, he currently leads the Biology R&D organization, driving the development of spatial biology and highly multiplexed analysis technologies aimed at clinical applications and large-scale operational deployment.
*This article was created based on publicly available information from RareCyte. Information is current as of the webinar announcement date.
